LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 8, 2016, Pages 2171-2180

  Vallejo, Juan A ^a   Martínez Guitián, Marta ^a   Vázquez Ucha, Juan C ^a   González Bello, Concepción ^b   Poza, Margarita ^a   Buynak, John D ^c   Bethel, Christopher R ^d   Bonomo, Robert A ^d,e   Bou, German ^a   Beceiro, Alejandro ^a  

^a Instituto de Investigaciones Biomédicas de A Coruña INIBIC   (Spain)

^b s n   (Spain)

^c SOUTHERN METHODIST UNIVERSITY   (United States)

^d LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEMASE; CLAVULANIC ACID; COLISTIN; ERTAPENEM; HYDROLASE INHIBITOR; IMIPENEM; LN 1 255; MEROPENEM; NITROCEFIN; OXA 48 CARBAPENEMASE; SULBACTAM; TAZOBACTAM; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; LN 1-255; OXACILLINASE; PENICILLIN DERIVATIVE; PROTEIN BINDING; SULFOXIDE;

ACYLATION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CATALYTIC EFFICIENCY; CONTROLLED STUDY; COVALENT BOND; DEACYLATION; DRUG POTENTIATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME PURIFICATION; ESCHERICHIA COLI; FRACTIONAL INHIBITORY CONCENTRATION INDEX; HYDROGEN BOND; HYDROLYSIS KINETICS; IC50; KINETICS; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR CLONING; MOLECULAR DOCKING; NONHUMAN; STATIC ELECTRICITY; STEADY STATE; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CARBAPENEMS; CLONING, MOLECULAR; CYCLIC S-OXIDES; ESCHERICHIA COLI; GENE EXPRESSION; KINETICS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PENICILLINS; PROTEIN BINDING; SULBACTAM;

EID: 84982204116     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw105     Document Type: Article

References (53)

1. The White House. National Strategy to Combat Antibiotic-Resistant Bacteria. 2014. http://www.cdc.gov/drugresistance/federal-engagementin- ar/national-strategy/index.html.
2. Bush K, Jacoby GA. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 2010; 54: 969-76.
3. Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 2010; 23: 320-6.
4. Walsh TR. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents 2010; 36 Suppl 3: S8-14.
5. Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrob Agents Chemother 2010; 54: 24-38.
6. Bonnin RA, Nordmann P, Poirel L. Screening and deciphering antibiotic resistance in Acinetobacter baumannii: a state of the art. Expert Rev Anti Infect Ther 2013; 11: 571-83.
7. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012; 67: 1597-606.
8. Nordmann P, Poirel L. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 2014; 20: 821-30.
9. Arana DM, Saez D, Garcia-Hierro P et al. Concurrent interspecies and clonal dissemination of OXA-48 carbapenemase. Clin Microbiol Infect 2015; 21: 148.e1-4.
10. Branas P, Villa J, Viedma E et al. Molecular epidemiology of carbapenemase-producing Klebsiella pneumoniae in a hospital in Madrid: successful establishment of an OXA-48 ST11 clone. Int J Antimicrob Agents 2015; 46: 111-6.
11. Grundmann H, Livermore DM, Giske CG et al. Carbapenem-nonsusceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010; 15: pii=19711.
12. Dortet L, Cuzon G, Nordmann P. Dissemination of carbapenemaseproducing Enterobacteriaceae in France, 2012. J Antimicrob Chemother 2014; 69: 623-7.
13. Nordmann P, Naas T, Poirel L. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791-8.
14. Oteo J, Miró E, Pérez-Vázquez M et al. Evolution of carbapenemaseproducing Enterobacteriaceae at the global and national level: what should be expected in the future? Enferm Infecc Microbiol Clin 2014; 32 Suppl 4: 17-23.
15. Canton R, Akova M, Carmeli Y et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012; 18: 413-31.
16. Glasner C, Albiger B, Buist G et al. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill 2013; 18: pii=20525.
17. Pitart C, Sole M, Roca I et al. First outbreak of a plasmid-mediated carbapenem-hydrolyzing OXA-48 β-lactamase in Klebsiella pneumoniae in Spain. Antimicrob Agents Chemother 2011; 55: 4398-401.
18. Potron A, Kalpoe J, Poirel L et al. European dissemination of a single OXA-48-producing Klebsiella pneumoniae clone. Clin Microbiol Infect 2011; 17: E24-6.
19. Poirel L, Bonnin RA, Nordmann P. Genetic features of the widespread plasmid coding for the carbapenemase OXA-48. Antimicrob Agents Chemother 2012; 56: 559-62.
20. Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol 2011; 6: 653-66.
21. Bradford PA, Kazmierczak KM, Biedenbach DJ et al. Colistin-resistant Enterobacteriaceae: correlation of β-lactamase production and colistin resistance among isolates from a global surveillance program. Antimicrob Agents Chemother 2015; 60: 1385-92.
22. Liu YY, Wang Y, Walsh TR et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2015; 16: 161-8.
23. Perez-Llarena FJ, Bou G. β-Lactamase inhibitors: the story so far. Curr Med Chem 2009; 16: 3740-65.
24. Zhanel GG, Lawson CD, Adam H et al. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 2013; 73: 159-77.
25. Drawz SM, Papp-Wallace KM, Bonomo RA. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 2014; 58: 1835-46.
26. Lahiri SD, Mangani S, Jahic H et al. Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48. ACS Chem Biol 2015; 10: 591-600.
27. Buynak JD. The discovery and development of modified penicillin- and cephalosporin-derived β-lactamase inhibitors. Curr Med Chem 2004; 11: 1951-64.
28. Buynak JD, Rao AS, Doppalapudi VR et al. The synthesis and evaluation of 6-alkylidene-2'β-substituted penam sulfones as β-lactamase inhibitors. Bioorg Med Chem Lett 1999; 9: 1997-2002.
29. Drawz SM, Bethel CR, Doppalapudi VR et al. Penicillin sulfone inhibitors of class D β-lactamases. Antimicrob Agents Chemother 2010; 54: 1414-24.
30. Bou G, Santillana E, Sheri A et al. Design, synthesis, and crystal structures of 6-alkylidene-2'-substituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase. J Am Chem Soc 2010; 132: 13320-31.
31. Pattanaik P, Bethel CR, Hujer AM et al. Strategic design of an effective β-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone. J Biol Chem 2009; 284: 945-53.
32. Barba MJ, Fernandez A, Vindel A et al. Brotes simultáneos producidos por una cepa de Klebsiella pneumoniae productora de CTX-M-15 y OXA-48 y por otra cepa diferente productora de CTX-M-15 en el Complejo Hospitalario Universitario A Coruña (CHUAC). In: Abstracts of the Eighteenth Spanish Meeting of Clinical Microbiology and Infectious Diseases, Valencia, 2014. Abstract 51, p. 42. Spanish Society of Clinical Microbiology and Infectious Diseases, Madrid, Spain.
33. Beceiro A, Maharjan S, Gaulton T et al. False extended-spectrum β-lactamase phenotype in clinical isolates of Escherichia coli associated with increased expression of OXA-1 or TEM-1 penicillinases and loss of porins. J Antimicrob Chemother 2011; 66: 2006-10.
34. Garcia-Sureda L, Juan C, Domenech-Sanchez A et al. Role of Klebsiella pneumoniae LamB porin in antimicrobial resistance. Antimicrob Agents Chemother 2011; 55: 1803-5.
35. Beceiro A, Perez-Llarena FJ, Perez A et al. Molecular characterization of the gene encoding a new AmpC β-lactamase in Acinetobacter baylyi. J Antimicrob Chemother 2007; 59: 996-1000.
36. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Tenth Edition: Approved Standard M07-A10. CLSI, Wayne, PA, USA, 2015.
37. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
38. Golemi D, Maveyraud L, Vakulenko S et al. Critical involvement of a carbamylated lysine in catalytic function of class D β-lactamases. Proc Natl Acad Sci USA 2001; 98: 14280-5.
39. Papp-Wallace KM, Winkler ML, Taracila MA et al. Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrob Agents Chemother 2015; 59: 3710-7.
40. Papp-Wallace KM, Mallo S, Bethel CR et al. A kinetic analysis of the inhibition of FOX-4 β-lactamase, a plasmid-mediated AmpC cephalosporinase, by monocyclic β-lactams and carbapenems. J Antimicrob Chemother 2014; 69: 682-90.
41. Bethel CR, Taracila M, Shyr T et al. Exploring the inhibition of CTX-M-9 by β-lactamase inhibitors and carbapenems. Antimicrob Agents Chemother 2011; 55: 3465-75.
42. Ehmann DE, Jahic H, Ross PL et al. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci USA 2012; 109: 11663-8.
43. Cambridge Crystallographic Data Centre. http://www.ccdc.cam.ac.uk/ products/life_sciencies/gold/.
44. King DT, Strynadka NCJ. The X-ray crystal structure is available fromthe Protein Data Bank (PDB: 4S2K). OXA-48 in complex with avibactam at pH 7.5. http://www.rcsb.org/pdb/explore/explore.do?structureId=4S2K.
45. Frisch GWT, Schlegel HB, Scuseria GE et al. Gaussian 09, Revision A.2. Wallingford, CT: Gaussian, 2009.
46. Bush K, Macalintal C, Rasmussen BA et al. Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob Agents Chemother 1993; 37: 851-8.
47. Poirel L, Castanheira M, Carrer A et al. OXA-163, an OXA-48-related class D β-lactamasewith extended activity toward expanded-spectrumcephalosporins. Antimicrob Agents Chemother 2011; 55: 2546-51.
48. Poirel L, Heritier C, Tolun V et al. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 15-22.
49. Docquier JD, Calderone V, De Luca F et al. Crystal structure of the OXA-48 β-lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol 2009; 16: 540-7.
50. Santillana E, Beceiro A, Bou G et al. Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proc Natl Acad Sci USA 2007; 104: 5354-9.
51. De Luca F, Benvenuti M, Carboni F et al. Evolution to carbapenemhydrolyzing activity in noncarbapenemase class D β-lactamase OXA-10 by rational protein design. Proc Natl Acad Sci USA 2011; 108: 18424-9.
52. Ehmann DE, Jahic H, Ross PL et al. Kinetics of avibactam inhibition against class A, C, and D β-lactamases. J Biol Chem 2013; 288: 27960-71.
53. DeLano WL. The PyMOL Molecular Graphics System. Palo Alto, CA: DeLano Scientific, 2008. http://www.pymol.org/.